ghk-cu peptide injection dosage protocol Guide 2026: mg/Week, Chart & ghk cu subcutaneous injectable peptide

Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and some anticonvulsants can all impair bone healing

Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks

The FDA lists BPC-157 as a Category 2 bulk drug substance, which limits where it can be legally compounded

Weaknesses in Existing Clinical Literature The available clinical literature on BPC-157 is sparse and fraught with methodological weaknesses

It does not create an approved drug label, an FDA-approved indication, standardized national dosing, a guarantee of insurance coverage, or a finding that every formulation and route is appropriate